Genflow Biosciences plc (LON: GENF)

Market Cap	5.16M
Revenue (ttm)	598.04K
Net Income (ttm)	-1.53M
Shares Out	349.71M
EPS (ttm)	-0.01
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,334,871
Open	1.490
Previous Close	1.475
Day's Range	1.466 - 1.650
52-Week Range	1.323 - 3.406
Beta	2.37
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 27, 2024

About Genflow Biosciences

Genflow Biosciences plc, together with its subsidiaries, operates as a biotechnology company that focuses on developing biological interventions aimed at tackling the effects of ageing, slowing, and halting the ageing process, and reducing the incidence of age-related diseases with increase in health span in the United Kingdom and Belgium. Its lead compound is GF-1002, a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. The company is also developing GF-3001, a topical delivery of SIRT6 to the skin; and...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Employees: 5
• Stock Exchange: London Stock Exchange
• Ticker Symbol: GENF